Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in treatment-naïve aHUS
NCT02949128Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2017
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in atypical hemolytic uremic syndrome (aHUS), sponsored by Alexion Pharmaceuticals. Primary endpoint: Percentage Of Participants With Complete Thrombotic Microangiopathy (TMA) Response at 26 weeks. Started Jan 2017; status: completed.
02
Drugs
ravulizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT02949128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949128.